-DOCSTART- -X- O
A -X- _ O
phase -X- _ O
II -X- _ O
trial -X- _ O
was -X- _ O
conducted -X- _ O
in -X- _ O
subjects -X- _ B-Patient
with -X- _ I-Patient
human -X- _ I-Patient
papillomavirus -X- _ I-Patient
( -X- _ I-Patient
HPV -X- _ I-Patient
) -X- _ I-Patient
associated -X- _ I-Patient
high- -X- _ I-Patient
grade -X- _ I-Patient
cervical -X- _ I-Patient
dysplasia -X- _ I-Patient
testing -X- _ O
the -X- _ O
safety -X- _ O
and -X- _ O
efficacy -X- _ O
of -X- _ O
a -X- _ O
microparticle -X- _ B-Intervention
encapsulated -X- _ I-Intervention
pDNA -X- _ I-Intervention
vaccine. -X- _ I-Intervention
Amolimogene -X- _ O
expresses -X- _ O
T -X- _ O
cell -X- _ O
epitopes -X- _ O
from -X- _ O
E6 -X- _ O
and -X- _ O
E7 -X- _ O
proteins -X- _ O
of -X- _ O
HPV -X- _ O
types -X- _ O
16 -X- _ O
and -X- _ O
18. -X- _ O
An -X- _ O
analysis -X- _ O
was -X- _ O
performed -X- _ O
on -X- _ O
a -X- _ O
subset -X- _ O
of -X- _ O
HLA-A2+ -X- _ B-Patient
subjects -X- _ I-Patient
to -X- _ O
test -X- _ O
whether -X- _ O
CD8+ -X- _ O
T -X- _ O
cells -X- _ O
specific -X- _ O
to -X- _ O
HPV -X- _ O
16 -X- _ O
, -X- _ O
18 -X- _ O
, -X- _ O
6 -X- _ O
and -X- _ O
11 -X- _ O
were -X- _ O
increased -X- _ O
in -X- _ O
response -X- _ O
to -X- _ O
amolimogene -X- _ O
immunization. -X- _ O
Of -X- _ O
the -X- _ O
21 -X- _ O
subjects -X- _ O
receiving -X- _ O
amolimogene -X- _ O
, -X- _ O
11 -X- _ B-Outcome
had -X- _ I-Outcome
elevated -X- _ I-Outcome
CD8+ -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
responses -X- _ I-Outcome
to -X- _ I-Outcome
HPV -X- _ I-Outcome
16 -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
18 -X- _ I-Outcome
peptides -X- _ I-Outcome
and -X- _ I-Outcome
seven -X- _ I-Outcome
of -X- _ I-Outcome
these -X- _ I-Outcome
also -X- _ I-Outcome
had -X- _ I-Outcome
increases -X- _ I-Outcome
to -X- _ I-Outcome
corresponding -X- _ I-Outcome
HPV -X- _ I-Outcome
6 -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
11 -X- _ I-Outcome
peptides. -X- _ I-Outcome
In -X- _ I-Outcome
addition -X- _ I-Outcome
, -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
primed -X- _ I-Outcome
and -X- _ I-Outcome
expanded -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
HPV -X- _ I-Outcome
18 -X- _ I-Outcome
peptide -X- _ I-Outcome
demonstrated -X- _ I-Outcome
cross- -X- _ I-Outcome
reactivity -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
corresponding -X- _ I-Outcome
HPV -X- _ I-Outcome
11 -X- _ I-Outcome
peptide. -X- _ I-Outcome
These -X- _ O
data -X- _ O
demonstrate -X- _ O
that -X- _ O
treatment -X- _ O
with -X- _ O
amolimogene -X- _ O
elicits -X- _ O
T -X- _ O
cell -X- _ O
responses -X- _ O
to -X- _ O
HPV -X- _ O
16 -X- _ O
, -X- _ O
18 -X- _ O
, -X- _ O
6 -X- _ O
and -X- _ O
11 -X- _ O
. -X- _ O

